CDNA

CareDx, Inc. is a precision medicine company focused on improving transplant patient outcomes through advanced diagnostic surveillance solutions. Headquartered in Brisbane, California, CareDx develops and commercializes non-invasive blood tests that detect transplant rejection and monitor organ health. The company's flagship product, AlloSure, is a donor-derived cell-free DNA (dd-cfDNA) surveillance solution for heart, kidney, and lung transplant recipients. AlloSure can detect rejection earlier than traditional methods, potentially enabling timely intervention and better patient outcomes. CareDx also offers AlloMap, a gene expression profiling test for heart transplant monitoring, and AlloSeq, a next-generation sequencing-based tissue typing solution. The company's comprehensive transplant surveillance platform includes software and services that support clinical decision-making and patient management. CareDx serves transplant centers, clinicians, and patients across the United States and internationally. The company's testing services are supported by clinical evidence and are increasingly integrated into post-transplant patient care protocols.